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Aim: Sodium-glucose cotransporter 2 inhibitors are novel antidiabetic agents that inhibit glucose reabsorption in the renal
proximal tubules. We assessed the potential effects of sodium-glucose cotransporter 2 inhibitors on body weight, hepatic fat
accumulation, and liver stiffness by using transient elastography (TE) and measuring biochemical markers associated with
nonalcoholic fatty liver disease (NAFLD) with type 2 diabetes mellitus (T2DM).
Methods: For 12 weeks, patients with T2DM and NAFLD were treated by ipragliflozin as an add-on medication. Physical
findings, biochemical blood and urinary analyses, meal tolerance test, and TE were assessed before and 12 weeks after the
administration of ipragliflozin.
Results: Fifteen patients were enrolled in this study. From baseline to 12 weeks, body mass index (BMI; p < 0.0001), hemo-
globin A1c (p < 0.01), and fasting and postprandial plasma glucose (p < 0.05 and p < 0.01, respectively) were significantly
reduced. Fasting C-peptide immunoreactivity index (p < 0.05), urinary glucose (p < 0.001), and hematocrit (p < 0.01) were
significantly increased. Uric acid (p < 0.01), γ-glutamyl transpeptidase (p < 0.05), ferritin (p < 0.001), hepatic fat accumula-
tion (i.e., the controlled attenuation parameter [CAP]; p < 0.05), and liver stiffness (E; p < 0.05) were significantly decreased,
as measured by TE. The percent change in BMI and the change in the aspartate aminotransferase, alanine aminotransferase
(ΔALT), and type IV collagen 7s levels, and in the aspartate aminotransferase-to-platelet ratio index and fibrosis-4 index val-
ues were correlated with the change in the CAP (ΔCAP). The ΔALT was the only independent predictor of ΔCAP, based on
multivariate analysis (p < 0.01).
Conclusions: The administration of the sodium-glucose cotransporter 2 inhibitor ipragliflozin may be associated with the
amelioration of hepatic steatosis and elasticity in patients with T2DM and NAFLD.
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Introduction
Nonalcoholic fatty liver disease (NAFLD) is a significant
health problem, and 20% of affected individuals have
nonalcoholic steatohepatitis (NASH), which is the most
severe form of NAFLD.
１
NASH predicts incidental car-
diovascular disease―independent of metabolic syndrome
or insulin resistance― and should be aggressively
treated.
２，３
Lifestyle interventions that result in weight loss
decrease the onset of type 2 diabetes mellitus (T2DM)
and cardiovascular events.
４，５
Hepatic fat reduction by
lifestyle intervention using exercise and restricted diet
usually requires at least a 5% loss in total body weight. A
decrease in body weight of approximately 3% may be as-
sociated with a significant improvement in hepatic stea-
tosis.
６，７
Simple weight loss by lifestyle intervention is dif-
ficult to achieve; therefore, bariatric surgery is an alterna-
tive treatment for body weight reduction.
８，９
Other phar-
macotherapeutic treatments are useful for some people
with fatty liver or NASH/NAFLD, although the effec-
tiveness of this approach is relatively limited or contro-
versial.
Sodium-glucose cotransporter 2 (SGLT 2 ) inhibitors
are novel antihyperglycemic agents. Through an insulin-
independent mechanism, these agents reduce the plasma
glucose concentration with a low risk of hypoglycemia,
and are associated with the loss of body weight.
１０，１１
We
focused on the potential effect of SGLT2 inhibitors on
reducing body weight and aimed to assess their effects on
hepatic fat accumulation and liver stiffness by using tran-
sient elastography (TE) and by measuring biochemical
markers associated with NAFLD in patients with T2DM.
Materials and Methods
Fifteen patients with T2DM and NAFLD who attended
Yachiyo Medical Center at Tokyo Women’s Medical
University (Chiba, Japan) were recruited. All patients
were diagnosed as having NAFLD, based on the guide-
lines of the American Association for the Study of Liver
Diseases (Alexandria, VA), American College of Gastro-
enterology (Bethesda, MD ) , and American Gastroen-
terological Association (Bethesda, MD).
７
Patients were
excluded if they had liver cirrhosis, viral hepatitis, auto-
immune hepatitis, α-1 antitrypsin deficiency, primary
biliary cirrhosis, hemochromatosis, Wilson disease, or
other secondary causes such as alcohol ingestion of more
than 20 g/day. Patients were also excluded if they had
chronic kidney disease (i.e., serum creatinine concentra-
tion >1.5 mg/dL) or had been treated with SGLT2 inhibi-
tors. Abdominal ultrasonography was used to confirm
whether the echogenicity of the liver exceeded that of the
renal cortex and spleen. In addition, there was an attenu-
ation of the ultrasound wave, loss in the definition of the
diaphragm, and poor delineation of the intrahepatic archi-
tecture, based on the standard criteria.
１２
The SGLT2 in-
hibitor ipragliflozin (50 mg/day) was added to the pa-
tient’s current treatment. The patient’s diet and exercise
therapy were not changed during this study. Laboratory
data, which included biochemical markers for NAFLD
and TE to measure the controlled attenuation parameter
(CAP) and liver stiffness (E), were obtained before and
12 weeks after the administration of ipragliflozin. The C-
peptide immunoreactivity index (CPI) was calculated as
100 times the C-peptide level (ng/mL) divided by the
plasma glucose level ( mg / dL ) . The aspartate
aminotransferase-to-platelet ratio index (APRI) and the
fibrosis-4 (FIB-4) index were calculated, as described in
previous reports.
１３，１４
The CAP and E were measured with the FibroScan
502 Touch system (Echosens, Paris, France) by using an
M-probe (3.5 MHz) , as described previously.
１５，１６
The
CAP and E are expressed in decibels/meter (dB/m) and
kilopascals (kPa), respectively. The mean values of the
CAP and E measurements were reliable when 10 valid
measurements were obtained and the interquartile range/
median ratio was <30%.
１７
Transient elastography is a
noninvasive method used to detect liver steatosis and fi-
brosis; its findings are correlated with the staging of liver
steatosis and fibrosis detected by using liver biopsy.
１５，１８
A test meal (JANEF E460F18; Kewpie Corp., Tokyo,
Japan) consisted of chicken in white sauce, crackers, and
soft pudding, and contained 450 kcal of total energy
(51.4% carbohydrates, 33.3% fat, and 15.3% protein). It
was developed by the Japanese Diabetes Society and
Kewpie Cooperation (Tokyo, Japan ) .
１９
Meal tolerance
tests were administered, as previously described.
２０，２１
In
brief, fasted patients ingested the test meal for 20 minutes
at breakfast. Blood samples were then collected at 0 min-
utes (i.e., before) and 60 minutes after the test meal load-
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Table　1　Clinical parameters at baseline.
Parameter Number of patients (n = 15) 
Sex, male/female [no (%) ] 11 (73%) /4 (27%) 
Age (y) 47.4±8.0 (36-64) 
Body weight (kg) 98.7±21.8 (70-147) 
BMI (kg/m2) 35.2±6.1 (25.4-49.1) 
Duration (y) 4.3±2.7 (1-10) 
HbA1c (NGSP) (%) 7.5±1.3 (6.1-11.1) 
Fasting plasma glucose (mg/dL) 145±40 (96-229) 
Hypertension 13 (86%) 
Dyslipidemia 10 (66%) 
Diabetic neuropathy 4 (27%) 
Diabetic retinopathy 2 (13%) 
Diabetic nephropathy 4 (27%) 
Smoking history 10 (67%) 
Concomitant medications
 Sulfonylurea 1 (7%) 
 Glinide 1 (7%) 
 Dipeptidyl peptidase-4 inhibitor 5 (33%) 
 α-Glucosidase inhibitor 3 (20%) 
 Biguanide 12 (80%) 
 Thiazolidinedione 1 (7%) 
 GLP-1 receptor agonist 2 (13%) 
 Insulin 0 (0%) 
BMI, body mass index; GLP-1, glucagon-like peptide-1; HbA1c, hemoglobin A1C.
All data are presented as the mean ± the standard deviation (range) or as the number 
(percentage).
ing. These steps were repeated before and at 12 weeks af-
ter the administration of ipragliflozin.
The protocol of this study conformed to the ethical
guidelines of the 2008 Declaration of Helsinki and was
approved by the ethics committee of Tokyo Women’s
Medical University (Tokyo, Japan ; approval # 3300 ) .
Each patient provided written informed consent.
Statistical analysis
The data are expressed as the mean± the standard de-
viation. The paired t-test was used to analyze significant
differences between the clinical data at baseline and at 12
weeks after ipragliflozin treatment. Correlation coeffi-
cients were calculated by using Pearson’s analysis for a
normal distribution and by using Spearman analysis for a
skewed distribution. Multivariate stepwise regression
analysis was used to identify factors affecting the de-
crease in hepatic fat accumulation by using changes (Δ)
in the CAP as the dependent variable and other parame-
ters that were detected with univariate analysis. Statisti-
cal analysis was conducted using JMP 12 (SAS Institute
Inc., Cary, NC, USA). For each parameter, the delta sym-
bol (Δ) represents the difference in values before and af-
ter initiating ipragliflozin. The percent change (%Δ) rep-
resents the ratio of the change in each parameter to its ba-
sal value before the administration of ipragliflozin.
Results
The characteristics of the studied patients are shown in
Table 1. The mean age was 47.4 years. The mean body
mass index (BMI) was 35.2 kg/m
2
(range, 25.4-49.1 kg/
m
2
).
The BMI and hemoglobin A1c (HbA1c) levels de-
creased by 0.6 kg/m
2
(p < 0.01) and 0.6% (p < 0.001), re-
spectively (Table 2). The urinary glucose level had in-
creased by 3,064 mg/dL (p < 0.001) at 12 weeks after the
administration of ipragliflozin. After the administration
of ipragliflozin, fasting plasma glucose concentrations
significantly decreased by 16 mg/dL (p < 0.05) and the
fasting CPI significantly increased by 0.25 (p < 0.05).
Postprandial plasma glucose levels and the postprandial
CPI during the meal tolerance tests were significantly de-
creased by 26 mg/dL (p < 0.01) and by 0.05 (p < 0.05),
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Table　2　The changes in metabolic parameters at baseline and 12 weeks after the administration of ipragliflozin.
Baseline 12 weeks
BMI (kg/m2) 35.2±6.1 34.6±5.9**
Systolic blood pressure (mmHg) 135.0±16.0 130.0±16.0
Diastolic blood pressure (mmHg) 88.0±10.0 86.0±12.0
HbA1c (NGSP) (%) 7.5±1.3 6.9±0.9***
Fasting plasma glucose (mg/dL) 145±40 129±24*
Postprandial plasma glucose (mg/dL) 219±41 193±35**
Fasting CPI 2.32±0.87 2.57±1.22*
Postprandial CPI 3.00±1.57 2.95±1.01*
Urinary glucose/Cre (mg/gCre) 62±138 3,126±2,081***
HDL cholesterol (mg/dL) 47±10 47±8
LDL cholesterol (mg/dL) 111±25 109±29
Triglycerides (mg/dL) 188±142 182±100
Uric acid (mg/dL) 6.4±1.3 5.8±1.2**
Hematocrit (%) 43.8±3.1 47.1±3.2***
AST (IU/L) 43±21 32±11
ALT (IU/L) 59±28 49±28
γGTP (IU/L) 75±72 55±34*
eGFR (mL/min) 87.2±21.4 82.2±19.0
NAG (IU/L) 21±25 12±8
Serum β2MG (mg/L) 1.7±0.2 1.8±0.2
Urinary β2MG (μg/L) 253±311 182±150
Ferritin (ng/mL) 128±58 77±39***
Hyaluronic acid (ng/mL) 27±17 30±15
Type IV collagen 7s (ng/mL) 4.2±1.0 3.9±0.7
APRI 0.49±0.26 0.40±0.11
FIB-4 index 1.03±0.43 0.95±0.29
β2MG, β2 microglobulin; γGTP, gamma-glutamyl transpeptidase; ALT, alanine aminotransferase; AST, aspartate ami-
notransferase; BMI, body mass index; CPI, C-peptide immunoreactivity index; CPR, C-peptide immunoreactivity; 
eGFR, estimated glomerular filtration rate; HbA1c, hemoglobin A1c; HDL, high-density lipoprotein; LDL, low-density 
lipoprotein; NAG, N-acetylglucosamine; APRI, AST to platelet ratio index.
CPI (CPR index) =100×CPR/plasma glucose.
*p < 0.05, ** p < 0.01, *** p < 0.001.
All data are presented as the mean ± the standard deviation.
respectively, at 12 weeks after the administration of ipra-
gliflozin, compared with the baseline values. Blood pres-
sure, high-density lipoprotein and low-density lipopro-
tein cholesterol concentrations, and the triglyceride con-
centration were not significantly different. However, the
uric acid level was significantly decreased by 0.6 mg/dL
(p < 0.01) and the hematocrit was significantly increased
by 3.3% (p < 0.001).
The estimated glomerular filtration rate and levels of
serum β2 microglobulin, urinary N-acetylglucosamine,
and urinary β2 microglobulin were not significantly dif-
ferent. Aspartate aminotransferase ( AST ) and alanine
aminotransferase ( ALT ) tended to decrease, although
there was no statistical difference. The serum γ-glutamyl
transpeptidase (γ-GTP) and ferritin levels were signifi-
cantly decreased by 20 IU/L (p < 0.05) and 51 ng/mL (p
< 0.001), respectively, whereas the concentrations of se-
rum hyaluronic acid and type IV collagen 7s, and the
APRI and FIB-4 index were not significantly different.
The CAP and E were measured by TE. These values
were significantly decreased by 14 dB/m and 1.35 kPa,
respectively, at 12 weeks after ipragliflozin treatment (p
< 0.05), compared with the baseline values (Figure 1).
There were no serious adverse events attributable to ipra-
gliflozin during this study.
The change in CAP (ΔCAP) was correlated with the
percent change in BMI (%ΔBMI; p < 0.05); the change
in the serum levels of aspartate aminotransferase (ΔAST;
p < 0.05), alanine aminotransferase (ΔALT; p < 0.01),
and type IV collagen 7s (p < 0.01); and the change in the
values of the aminotransferase-to-platelet ratio index
(ΔAPRI; p < 0.05) and fibrosis-4 (ΔFIB-4) index (p <
0.05) (Table 3). However, it was not correlated with pa-
rameters associated with HbA1c, glucose levels, and fer-
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Figure　1　The controlled attenuation parameter (CAP) and stiffness (E) values, as measured by tran-
sient elastography at baseline and 12 weeks after the administration of ipragliflozin (the mean ± the 
standard deviation).
*p < 0.05.
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Table　3　Relationships between Δ CAP and changes in metabolic parameters.
Variables Correlation coefficient p
%ΔBMI 0.598 0.040*
ΔHbA1c 0.206 0.520
ΔFasting plasma glucose 0.119 0.712
ΔFasting CPI −0.423 0.188
ΔHematocrit −0.005 0.987
ΔUric acid 0.043 0.895
ΔAST 0.674 0.016*
ΔALT 0.716 0.009**
ΔγGTP 0.001 0.997
Δferritin 0.170 0.598
ΔType IV collagen 7s 0.752 0.008**
ΔAPRI 0.691 0.013*
ΔFIB-4 index 0.585 0.046*
*p < 0.05, ** p < 0.01.
ritin.
Multivariate regression analyses revealed that ΔALT
was the only independent predictor of ΔCAP (β = 0.716;
t = 3.24; 95% CI, 0.447-2.416; p = 0.009). However, no
parameters were identified as an independent determinate
of the change in liver stiffness (ΔE).
Discussion
In our study, at 12 weeks after treatment with the SGLT2
inhibitor ipragliflozin, we used TE and observed an im-
provement in hepatic fat accumulation and elasticity in
patients with T2DM and NAFLD. The BMI was associ-
ated with the CAP. A predictor for improving CAP could
be ALT and type IV collagen 7s.
A reduction in nutritional intake and in body weight
effectively treats NAFLD.
２２，２３
However, hepatic fat reduc-
tion only by lifestyle interventions such as maintaining a
reduced body weight is difficult to achieve and is some-
times unsustained.
２２，２３
The effects of some pharmaco-
therapeutic drugs such as vitamin E,
２４
metformin,
２５，２６
thia-
zolidinedione derivatives,
２７
and glucagon-like peptide-1
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analogs
２８，２９
are relatively limited or controversial. In a
previous report
２７
of patients with T 2 DM, histological
findings, which were obtained after 6 months of treat-
ment with a hypocaloric diet (a reduction of 500 kcal/day
in relation to the calculated daily intake required to main-
tain body weight) plus pioglitazone (45 mg/day) or a pla-
cebo, revealed that liver steatosis, ballooning necrosis,
and intrahepatic inflammation improved with pioglita-
zone, compared with a placebo. However, pioglitazone
induced an increase in the body weight from the baseline
(i.e. , pretreatment) weight, whereas the placebo group
had no significant change in the body weight.
Vitamin E (800 IU/day) is also efficient in treating
NASH, compared with a placebo and pioglitazone.
２４
The
glucagon-like peptide-1 analog liraglutide has been stud-
ied for T2DM treatment.
３０
In addition, liraglutide mono-
therapy (1.2 mg/day or 1.8 mg/day) reduced body weight
by approximately 2.0-3.2 kg.
３０
In one study,
３０
the liver-to-
spleen attenuation ratio increased after treatment with li-
raglutide (1.8 mg) and metformin. This increase indi-
cated reduced hepatic steatosis. These medical treatments
for fatty liver also need to accompany diet therapy and
exercise.
In recent years in Japan, obesity has been rapidly in-
creasing in younger patients with T 2 DM.
３１
Therefore,
early intervention for obesity with T2DM and fatty liver
may be necessary for preventing cardiovascular disease
and cancer, which are expected to increase in the future.
Based on this background, we studied the effect of ipra-
gliflozin on hepatic fat content and liver stiffness meas-
urements of patients who did not change their diet and
exercise therapy.
The SGLT2 inhibitors are extensively used worldwide
to treat T2DM. They effectively reduce the blood glucose
level and body weight owing to the excretion of approxi-
mately 50-60 g / day urinary glucose, which is nearly
equivalent to a daily caloric loss of 200-240 kcal/day. In
our study, the BMI was reduced by 0.6 kg/m
2
after 12
weeks of treatment, and the serum AST and ALT levels
tended to decrease. Additional improvement in body
weight and aminotransferase levels may be expected at
more than 12 weeks after the administration of ipragli-
flozin, followed by an improvement in the HbA1c level.
Changes in the ALT levels were strongly correlated
with the liver fat content but not with inflammation, he-
patocyte ballooning, or fibrosis.
３２
Therefore, it has been
proposed that serum ALT may enable the detection of
NAFLD.
３３
These reports support our findings that de-
creasing the CAP was associated with decreasing the
ALT level, after the potential amelioration of NAFLD.
After administering ipragliflozin, the intrahepatic fat
content and liver elasticity improved, based on the TE re-
sults. The expression of SGLT2 has been identified to a
much lesser extent in the liver than in the kidney,
３４
which
suggests that decreased body weight is partly associated
with a decline in the hepatic fat content that is part of ec-
topic fat accumulation.
Liver biopsy remains the gold standard for diagnosing
NASH and staging fibrosis in patients with NAFLD ;
however, repeated liver biopsy is difficult to perform be-
cause it is an invasive method. Measuring liver stiffness
and elasticity with TE is a noninvasive and effective
method for screening patients with NAFLD. However,
the main limitation of TE is its failure to obtain reliable
liver stiffness measurements.
３５
In this study, to avoid this
factor as much as possible, at least 10 valid measure-
ments were obtained to determine reliable mean values
for CAP and E.
A substantial amount of previous data indicates that
liver fibrosis is potentially reversible in chronic liver dis-
eases.
３６
Adipokines, chemokine, and/or insulin resistance
contribute to and are associated with liver fibrosis in
NAFLD.
３７
Leptin signaling promotes hepatic stellate cell
activity and amplifies fibrogenic activity through sup-
pressing peroxisome proliferator-activated receptor
gamma or downregulating adiponectin.
３８
Serum leptin
levels are much higher in patients with NASH or
NAFLD than in control patients, which suggests leptin
resistance.
３８
A mouse model of NAFLD exhibited insulin
resistance and increased free fatty acid (FFA ) levels,
which have an important role in liver steatosis; the ad-
ministration of SGLT2 inhibitors ameliorated these lev-
els.
３９
Some previous research indicates that SGLT2 inhibi-
tors may be beneficial for the prevention and progression
of liver fibrosis in vivo;
３９，４０
however, no large clinical tri-
als have concluded that SGLT2 inhibitors have an anti-
hepatic fibrosis effect in humans. Leptin and FFA levels
improve after the administration of SGLT2 inhibitors in
humans.
４１
Therefore, SGLT2 inhibitors may ameliorate
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liver steatosis. In our study, leptin and FFA were not
measured. In addition, the amelioration of liver elasticity,
as measured by TE, was incongruous with the lack of
change in the APRI and FIB-4 index values. This incon-
gruous finding may have been caused by the fact that
liver fibrosis in our patients was mild at the beginning of
the study and the study period was short. The details of
the mechanisms for the improvement in liver elasticity in
humans remain unclear. Therefore, further investigations
on this issue are needed.
The serum ferritin concentration decreased signifi-
cantly. In women, the serum ferritin concentration varies
because of menstruation. Therefore, we analyzed ferritin
data only in men, and found a significant difference (133
± 57 versus 70± 43 ng/mL, p < 0.001). Serum ferritin
concentration is not only a clinical marker of iron stor-
age, but inflammation in several tissues, and is especially
increased in NASH.
４２
Renal tubular function, as indicated by β2 microglobu-
lin and N-acetylglucosamine levels, did not change in our
study. In an in vitro study,
４３
the inhibition of SGLT2 was
protective against oxidative stress induced by high glu-
cose concentrations in incubated cultured tubular cells.
The average baseline renal tubular functions were near
normal in our study. The protective effects of ipragli-
flozin on renal tubular function may be more prominent
in people with injured tubular function and during a long
period of treatment with SGLT2 inhibitors.
There were several limitations in our study. First, this
single-arm clinical study involved no placebo and control
groups. Second, only a small number of patients was
studied. Third, histological examinations did not include
liver biopsies, which may have directly revealed the ame-
lioration of hepatic fat accumulation and elasticity. We
recognize that a multi-arm clinical trial with a larger
number of patients and longer study periods are needed
to clarify the potential effect of an SGLT2 inhibitor on
ameliorating hepatic steatosis and elasticity.
In Japan, SGLT2 inhibitors can be used for treating T2
DM. We previously reported that people with type 1 dia-
betes and a fatty liver have more cardiovascular risk fac-
tors.
４４
In the future, this drug may be indicated for people
with fatty liver or NASH/NAFLD to prevent cardiovas-
cular diseases.
Conclusion
The treatment for NAFLD, especially diet therapy, is
clinically difficult for people with T2DM. Through their
effects on reducing body weight and ameliorating hepatic
steatosis and fibrosis, SGLT2 inhibitors may be a medi-
cal intervention that can be added to ongoing treatment
with medicine, diet, and exercise therapy.
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